Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, multicenter, long-term extension study to compare the safety and efficacy of TAK-385 (10, 20, and 40 mg) following oral administration for 12 weeks or more in the treatment of endometriosis

Next Previous
Trial Profile

A Phase II, multicenter, long-term extension study to compare the safety and efficacy of TAK-385 (10, 20, and 40 mg) following oral administration for 12 weeks or more in the treatment of endometriosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relugolix (Primary) ; Leuprorelin
  • Indications Endometriosis
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Takeda

    • Most Recent Events

    • 24 May 2017 According to a Myovant Sciences media release, results from the study were presented during a poster presentation at the 2017 European Congress of Endocrinology.
    • 24 May 2017 Results published in a Myovant Sciences media release.
    • 18 May 2017 According to a Myovant Sciences media release, 24 week extension data will be presented at the 19th European Congress of Endocrinology (ECE) 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top